PharmaPoint: Dry Eye Syndrome - US Drug Forecast and Market Analysis to 2022

Share Article

Reportbuyer.com just published a new market research report: PharmaPoint: Dry Eye Syndrome - US Drug Forecast and Market Analysis to 2022.

PharmaPoint: Dry Eye Syndrome - US Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, “PharmaPoint: Dry Eye Syndrome - US Drug Forecast and Market Analysis to 2022”. Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation. The most common symptoms of DES are ocular irritation and discomfort, foreign body sensation, fatigue, and visual disturbances, which interfere with daily activities. In the elderly population, it is the most common reason for seeking eye care, and this is expected to increase exponentially with an aging demographic.

Overall, the DES market in the US will grow substantially during the forecast period due to the emergence of new products, a larger patient population, and increased physician awareness of the disease. The current US market for DES is dominated by Restasis, in addition to as-needed relief with artificial tears.

Scope

-Overview of the DES including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
-Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
-Sales forecast for the top drugs in the US from 2012-2022.
-Analysis of the impact of key events as well the drivers and restraints affecting the US DES market.

Reasons to buy

-Understand and capitalize by identifying products that are most likely to ensure a robust return
-Stay ahead of the competition by understanding the changing competitive landscape for DES
-Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
-Make more informed business decisions from insightful and in-depth analysis of drug performance
-Obtain sales forecast for drugs from 2012-2022 in the US.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 12
3.1.3 Classification 14
3.1.4 Prognosis 15
3.1.5 Quality of Life 15
3.2 Symptoms 16
4 Disease Management 17
4.1 Overview 17
4.1.1 Diagnosis Overview 17
4.1.2 Treatment Guidelines 19
4.1.3 Treatment Overview 24
4.2 US 27
4.2.1 Diagnosis 27
4.2.2 Clinical Practice 27
5 Competitive Assessment 29
5.1 Overview 29
5.2 Strategic Competitor Assessment 29
5.3 Product Profiles – Major Brands 31
5.3.1 Restasis (cyclosporine 0.05% ophthalmic emulsion) 31
5.3.2 Mucosta (rebamipide 2% ophthalmic suspension) 35
5.3.3 Additional Therapies 38
6 Opportunity and Unmet Need 42
6.1 Overview 42
6.2 Diagnostic tests are not specific enough to identify subgroups of patients 43
6.3 Frequent dosing and side effects limit compliance 44
6.4 Lack of physician and patient awareness 45
6.5 Trial design may be a factor in so few drugs being approved 46
6.6 Unmet Needs Gap Analysis 47
6.7 Comprehensive method for measuring dry eye signs and severity levels 48
6.8 Increase treatment rates among milder forms of the disease 49
7 Pipeline Assessment 50
7.1 Overview 50
7.2 Promising drugs in clinical development 51
7.2.1 Lifitegrast 52
7.2.2 CF-101 55
7.2.3 Cyclokat 59
7.2.4 EGP-437 62
7.2.5 RX-10045 65
7.2.6 MIM-D3 68
8 Market Outlook 72
8.1 United States 72
8.1.1 Forecast 72
8.1.2 Key Events 75
8.1.3 Drivers and Barriers 75
9 Appendix 78
9.1 Bibliography 78
9.2 Abbreviations 81
9.3 Methodology 83
9.4 Forecasting Methodology 83
9.4.1 Diagnosed DES patients 83
9.4.2 Percent Drug-treated Patients 84
9.4.3 Drugs Included in Each Therapeutic Class 84
9.4.4 Launch and Patent Expiry Dates 84
9.4.5 General Pricing Assumptions 85
9.4.6 Individual Drug Assumptions 86
9.4.7 Generic Erosion 89
9.5 Physicians and Specialists Included in this Study 90
9.6 About the Authors 91
9.6.1 Author 91
9.6.2 Global Head of Healthcare 92
9.7 About GlobalData 93
9.8 Contact Us 93
9.9 Disclaimer 93
1.1 List of Tables

Table 1: Symptoms of Dry Eye Syndrome 16
Table 2: Treatment Guidelines for Dry Eye Syndrome 24
Table 3: Commonly Prescribed Drugs for Dry Eye Syndrome by Class in the Global Markets, 2012 26
Table 4: Leading Treatments for Dry Eye Syndrome, 2012 30
Table 5: Product Profile – Restasis 32
Table 6: Restasis SWOT Analysis, 2012 35
Table 7: Product Profile – Mucosta 36
Table 8: Mucosta SWOT Analysis, 2012 38
Table 9: Summary of Minor Drug Classes, 2012 41
Table 10: Overall Unmet Needs – Current Level of Attainment 43
Table 11: Clinical Unmet Needs – Gap Analysis, 2012 48
Table 12: Dry Eye Syndrome – Phase Pipeline, 2012 51
Table 13: Comparison of Therapeutic Classes in Development for Dry Eye Syndrome, 2012 52
Table 14: Product Profile – Lifitegrast 53
Table 15: Lifitegrast SWOT Analysis, 2012 55
Table 16: Product Profile – CF101 56
Table 17: CF101 SWOT Analysis, 2012 58
Table 18: Product Profile – Cyclokat 60
Table 19: Cyclokat SWOT Analysis, 2012 62
Table 20: Product Profile – EGP-437 63
Table 21: EGP-437 SWOT Analysis, 2012 65
Table 22: Product Profile – RX-10045 66
Table 23: RX-10045 SWOT Analysis, 2012 68
Table 24: Product Profile – MIM-D3 69
Table 25: MIM-D3 SWOT Analysis, 2012 71
Table 26: Sales Forecasts ($m) for Dry Eye Syndrome in the United States, 2012–2022 73
Table 27: Key Events Impacting Sales for Dry Eye Syndrome in the United States, 2012–2022 75
Table 28: United States, Dry Eye Syndrome Market – Drivers and Barriers, 2012–2022 75
Table 29: Key Launch Dates 84
Table 30: Key Patent Expiries 84
1.2 List of Figures

Figure 1: Dry Eye Syndrome – Disease Etiology 12
Figure 2: Tear Film in Normal Eye and Dry Eye 13
Figure 3: Sequence of Diagnostic Tests Used to Diagnose Dry Eye Syndrome 17
Figure 4: Delphi Panel Treatment Recommendations for Dysfunctional Tear Syndrome Without Lid Margin Disease, 2006 20
Figure 5: Delphi Panel Treatment Recommendations for Dysfunctional Tear Syndrome With Lid Margin Disease and Abnormal Tear Distribution, 2006 21
Figure 6: Treatment Recommendations for Dry Eye Syndrome from the Management and Therapy Subcommittee, Dry Eye Workshop, 2007 22
Figure 7: American Academy of Ophthalmology Preferred Practice Pattern for Dry Eye, 2011 23
Figure 8: Competitive Assessment of Late-Stage Pipeline Agents in Dry Eye Syndrome, 2012–2022 51
Figure 9: Sales for Dry Eye Syndrome in the United States by Drug Class, 2012–2022 74

Read the full report:

PharmaPoint: Dry Eye Syndrome - US Drug Forecast and Market Analysis to 2022

http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_dry_eye_syndrome_us_drug_forecast_market_analysis_2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sarah Smith
Research Advisor at Reportbuyer.com
+44 208 816 85 48
Email >
Visit website